Merck & Co., Inc. (Form: 8-K)  

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     
Date of Report (Date of Earliest Event Reported):   September 30, 2004

Merck & Co., Inc.
__________________________________________
(Exact name of registrant as specified in its charter)

         
New Jersey   1-3305   22-1109110
_____________________
(State or other jurisdiction 		  _____________
(Commission 		  ______________
(I.R.S. Employer
of incorporation)   File Number)   Identification No.)
          
One Merck Drive, P.O. Box 100, Whitehouse Station, NJ       08889
_________________________________
(Address of principal executive offices) 		      ___________
(Zip Code)
     
Registrant’s telephone number, including area code   908-423-1000

Not Applicable
______________________________________________
Former name or former address, if changed since last report

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Top of the Form

Item 8.01. Other Events.

Incorporated by reference is a press release issued by the Registrant on September 30, 2004, attached as Exhibit 99, concerning the Registrant's announcement of a voluntary worldwide withdrawal of VIOXX (rofecoxib), its arthritis and acute pain medicine.





Item 9.01. Financial Statements and Exhibits.

(c) Exhibits

Exhibit 99 - Press Release issued September 30, 2004





Top of the Form

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

         
    Merck & Co., Inc.
(Registrant)
          
October 1, 2004   By:   /s/ Debra A. Bollwage
       
        Name: /s/ Debra A. Bollwage
        Title: Assistant Secretary

Top of the Form

Exhibit Index


     
Exhibit No.   Description
 
EX-99
  Press Release issued September 30, 2004